Purpose: There are limited data on the cost of infections among patients with primary immunodeficiency disease (PIDD) in clinical practice. The purpose of this study was to assess the economic impact, from the US commercial payer perspective, of infections in a cohort of patients with PIDD who were administered intravenous immunoglobulin (IVIG) therapy. 
Introduction
Primary immunodeficiency disease (PIDD) refers to a group of genetic disorders in which essential functions of an individual's immune system are intrinsically impaired. Defects can be inherent in cells such as T lymphocytes, B lymphocytes, or phagocytic cells, consequently inhibiting an individual's ability to produce antibodies or fight infection. As a result, patients with PIDD face an increased susceptibility to infection (ie, prolonged, frequent, or uncommonly severe infections). 1 Data from a telephone survey conducted by the Immune Deficiency Foundation estimate the prevalence of PIDD to be approximately one in 1,200 individuals in the United States (ie, 250,000 people). 2 However, the prevalence is believed to be underestimated due to a high rate of underdiagnosis. A cohort study conducted from submit your manuscript | www.dovepress.com
Dovepress

298
Menzin et al 1976 through 2006 showed the incidence of PIDD to be 4.6 per 1,000,000 person-years, with rates increasing in more recent years, due to better diagnostic techniques and awareness among medical providers. 3 For patients with significantly low immunoglobulin (Ig) production levels (IgG levels of less than 200 mg/dL), intravenous Ig (IVIG) therapy is a common and effective treatment for providing increased immunity. 4 The infused antibodies that are administered by IVIG are naturally metabolized, therefore requiring repeat doses at regular intervals over a patient's lifetime. 4 The benefits of IVIG therapy are temporary, with IgG levels fluctuating from peak to trough throughout the typical 3-to 4-week dosing interval, and the risk of infection among patients with PIDD can still be prevalent during therapy.
PIDD can have a significant impact on a patient's quality of life, as well as present a substantial economic burden to patients and the health care system. A survey conducted by the Jeffrey Modell Centers Network in 64 countries across six continents found that in the year prior to diagnosis, the average patient with undiagnosed PIDD experienced 70 physician/ emergency room (ER) visits, 19 hospitalizations, and 34 missed days of school/work annually. 5 These figures improved with proper diagnosis and treatment but still presented a significant burden on patients (eg, 12 ER visits and five hospitalizations annually with proper diagnosis and treatment). The majority of published data on the costs associated with the condition focus on the direct medical expenditures associated with Ig therapy. 6, 7 However, with infections being common among this patient population, even among those receiving IVIG therapy (eg, over two infections per patient per year on average, with some episodes leading to a hospitalization), 8 it is important to also determine the economic burden associated with chronic infections. Published data on the cost of infections in clinical practice are limited; therefore, this study set out to assess the economic impact -from the US commercial payer perspective -of infections in a cohort of PIDD patients who were administered IVIG therapy. The findings will help to establish a more comprehensive estimate of the economic burden of PIDD to the US health care system. This time period was chosen to maximize the number of patients in the sample, given the relatively low prevalence of PIDD. Other selection criteria required during the study period included: diagnosis of at least one bacterial and/or nonbacterial/unspecified infection, continuous eligibility, no receipt of a prescription for subcutaneous Ig therapy (ie, in order to ensure the same route of Ig administration for each patient, given differences in the adverse event profiles), 4 and no diagnoses of immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, B cell chronic lymphocytic leukemia, or Kawasaki disease (ie, given that these conditions are also treated by IVIG therapy).
Methods
Patient selection
study measures
Study patients were described in terms of demographic and clinical characteristics. Patient demographic characteristics included age, sex, metropolitan statistical area, and geographic region. Clinical characteristics included an assessment of infection type and the presence of selected comorbid conditions. Infection types included blood (eg, sepsis), lung (eg, pneumonia, respiratory syncytial virus, etc), other (eg, infectious enteritis, helicobacter pylori, etc), and unspecified viral or bacterial organisms (eg, infections indicated but not otherwise specified).
The primary outcome measures included infectionrelated resource utilization and infection-related medical 
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Cost of infections in PiDD expenditures incurred during the 7-month study window. Resource utilization was measured in terms of inpatient hospitalizations, ER visits, outpatient visits, and other resource use, defined as assisted living facility, skilled nursing facility, independent clinic, state/local public health clinic, and rural health clinic. The proportion of patients using specified services and the frequency of use were assessed. In addition, infection-related medical expenditures were assessed in total and for each component of care, as defined above. Infectionrelated resource utilization and medical expenditures were determined by the presence of an infection diagnosis code (primary or any diagnosis) on a claim. All medical expenditures represent 2010 US dollars.
Since the primary aim of our study was to assess infectionrelated costs associated with the various components of care, data were analyzed at the medical claim level. Data were not further categorized into mutually exclusive infection episodes, which can be challenging using administrative claims data alone. As a result, direct comparisons of the incidence rates for infection cannot be made to the current literature.
statistical analyses
Descriptive statistics were assessed for patients' demographic and clinical characteristics as well as for each outcome measure. Continuous variables were summarized using mean, standard deviation (SD), median, and interquartile range values. Binary or categorical variables were summarized using percentages.
Given that hospitalizations have been shown to be a significant component of overall resource utilization for patients with PIDD, multivariate analyses were conducted to determine the predictors of infection-related hospitalization expenditures. 5 Adjusted infection-related hospitalization expenditures were estimated using a generalized linear model with a negative binomial distribution and a log link, controlling for age, sex, and the presence of selected comorbidities. Due to common characteristics observed in health care cost data, such as a highly skewed distribution from the small percentage of patients with extremely high expense rates, the generalized linear model is highly recommended for models using administrative claims data. 10 The presence of blood and lung infection types were also controlled for in separate multivariate regression models, as patients may have had more than one infection type. The models were conducted at the hospitalization level, instead of at the patient level as some patients may have had more than one infection-related hospitalization.
All analyses were performed using Statistical Analysis System (SAS) software package, version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
A total of 1,742 patients with a diagnosis of PIDD and consistent IVIG use were identified in the database; of these, 490 patients had resource utilization indicative of at least one infection during the 7-month study period. Mean age (± SD) among the 490 patients in the final study sample was 43.0 years (±18.4), and the majority of patients were female (58.8%) ( Table 1 ). The most prevalent comorbid conditions in this population included asthma (29.4%), the presence of any primary malignancy (25.1%), and diabetes with chronic complications (13.5%). A total of 40.4% of patients experienced a lung infection during the study period, and 11.8% of patients experienced a blood infection.
The predominant type of infection-related resource use was outpatient care, with 440 (89.8%) patients having one or more infection-related office visit(s) (mean office visits among patients with an office visit was 2.96 per patient). A further 123 (25.1%) patients experienced an infectionrelated inpatient hospitalization, with a mean of 1.38 hospitalizations per patient (median hospital days: 6.5; interquartile range: 4.0-12.0) among those hospitalized. Only 22 patients (4.5%) had an infection-related ER visit (not hospitalized) ( Table 2) .
The mean total infection-related medical expenditures over the 7-month study window were US$11,925 (±$37,498) per patient. Infection-related inpatient hospitalizations were the most expensive component of care, at US$38,574 per hospitalized patient, followed by outpatient visits (US$1,460 per patient with an outpatient visit) and ER visits (US$899 per patient with an ER visit) ( Table  2 ). In the first multivariate regression, the presence of a blood infection during the hospitalization (versus [vs] no blood infection), having diabetes, and younger age (,18 vs 55-64 years of age) were associated with significant increases in infection-related hospitalization expenditures (49.3%, 55.3%, and 76.5%, respectively) (P,0.05), among those patients experiencing an infection-related hospitalization (Table 3) . A second multivariate regression was conducted to test the impact of a lung infection during the hospitalization (vs no lung infection) on infection-related expenditures. While younger age and diabetes were still associated with significant increases in infection-related hospitalization expenditures in this model, the presence of a lung infection during the hospitalization was not a significant predictor (Table 4) .
Discussion
There are limited data on infection-related costs experienced by patients with PIDD, with available economic data focusing Other resource use includes nonoffice visit outpatient resource use consisting of: assisted living facility, skilled nursing facility, independent clinic, state/local public health clinic, and rural health clinic, among miscellaneous care types. Total infectionrelated medical expenditures were determined by the presence of an infection diagnosis code (primary or any diagnosis) on any medical claim, and represents the expenditures associated with these infection-related claims. This estimate does not reflect a cost estimate per infection episode. 
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Menzin et al on all-cause resource use or the direct cost of therapy. 6, 7, 11 A recent report from the Jeffrey Modell Foundation estimated annual infection-related charges to be $18,368 per patient, among those who received a PIDD diagnosis. 5 The study used results from a patient survey to determine the average number of infections experienced, among PIDD patients, and then applied the charges associated with the infections using data from the Hospital Cost and Utilization Project (HCUP), 5 which represents hospital billing information. The cost estimate produced in the Modell publication is slightly lower than the annualized infection-related medical costs (ie, payments to providers) observed in our study ($20,443) .
Our study is subject to certain limitations that are common to all studies that rely on retrospective claims data, such as potential coding errors and incomplete data. In order to maximize the sample size for analysis, only 7 months of continuous data were required for patient selection. Long-term data for a larger sample of patients with PIDD would be valuable for further economic analysis among this patient population. Furthermore, we were unable to assess infection episodes in our study, which may be defined by multiple resource-use events (eg, inpatient hospitalization followed by an outpatient visit may have been grouped into a single infection episode). Instead, we identified resource-use events with any diagnosis code for an infection, in order to analyze infection-related costs according to place of service. Given this methodological limitation, an incidence rate for infections could not be determined. Additionally, IVIG dosing and resulting levels were not available in this data set. This information would have been useful to further define treatment patterns, given that IVIG dosing must be individualized to minimize infection.
The results of our study suggest that health care expenditures for infections in PIDD patients receiving IVIG therapy can be substantial, particularly for inpatient care. The total cost of hospitalizations per patient after diagnosis of PIDD has been estimated at approximately $8,000 annually, based on data from patient surveys. 5 Our analysis provides real-world data on the expenditures of patients with PIDD, a data point that is limited in the published literature. These results will be beneficial for health policy decision makers tasked with evaluating the cost effectiveness of IVIG therapy, which has been estimated at approximately $30,000 per patient annually. 5 Future evaluations to assess the incremental cost of optimizing IVIG therapy (eg, adjusting dosing and/or achieving sustained steady-state levels) should include an evaluation of the effects on infection-related medical expenditures.
